ClinicalTrials.gg
CompletedNCT05030311REMIX-1Updated Apr 8, 2025Results posted

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

A Phase 3 interventional study of LOU064 25 mg (b.i.d) and Placebo in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 112 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
2nd of 12
470 · median 347
Started
2021
with 1 other
Phase 3
9 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 2nd largest by enrollment, is one of 2 that started in 2021, is one of 9 in phase 3, and was the 3rd registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.

Read the detailed description

This was a global Phase III multi-centered, randomized,double-blind, parallel-group, placebo-controlled study investigating the safety, tolerability, and efficacy of remibrutinib (25 mg b.i.d.) in adult patients with CSU inadequately controlled by second generation H1-antihistamines (H1-AHs). The study consisted of four periods, the total study duration was up to 60 weeks: Screening period of up to 4 weeks, Double-blind placebo-controlled treatment period of 24 weeks, Open-label treatment period with remibrutinib period of 28 weeks, and treatment-free follow-up period of 4 weeks. The planned sample size was approximately 450 patients randomized in 2:1 ratio to remibrutinib or placebo arm (300 in the remibrutinib arm and 150 in placebo arm).

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • BTK inhibitor
  • Chronic spontaneous urticaria
  • Urticaria activity score
  • Hives severity score
  • Itch severity score
  • CSU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male and female adult participants ≥18 years of age.
  • CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation).
  • Diagnosis of CSU inadequately controlled by second generation H1 antihistamines at the time of randomization defined as:
  • The presence of itch and hives for ≥6 consecutive weeks prior to screening despite the use of second generation H1-antihistamines during this time period
  • UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0-21) ≥ 6 during the 7 days prior to randomization (Day 1)
  • Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants medical history).
  • Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol.
  • Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1).

Exclusion criteria

Exclusion Criteria:

  • Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
  • Evidence of cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, (NYHA) Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding, e.g. in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g. requiring hospitalization or blood transfusion)
  • Requirement for anti- medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel. The use of dual anti-platelet therapy (e.g. acetylsalicylic acid + clopidogrel) is prohibited.
  • Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants (NOAC))
  • History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x (ULN) or (INR) of more than 1.5 at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
470 participants (actual)

Study arms

  • Experimental
    LOU064 25mg b.i.d.

    Patients initially randomized to Remibrutinib during the Double-blind treatment period and continued Remibrutinib during the Open-label treatment period (Up to Week 52)

    Drug: LOU064 25 mg (b.i.d) · Drug: LOU064 25 mg (b.i.d) as a tablet.

  • Placebo comparator
    Placebo

    Patients initially randomized to Placebo (Up to Week 24)

    Drug: Placebo · Drug: LOU064 25 mg (b.i.d) as a tablet.

Interventions

  • LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.

    Also known as: remibrutinib

  • DrugPlacebo

    Placebo

  • LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.

    Also known as: remibrutinib

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)

    The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0. This endpoint is a secondary endpoint for testing strategy Scenario 2 with Weekly Itch Severity Score (ISS7) and Weekly Hives Severity Score (HSS7) as co-primary efficacy endpoints).

    Time frame: Baseline, Week 12

  2. Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)

    The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity). This endpoint is a secondary endpoint for testing strategy Scenario 1 with Weekly Urticaria Activity Score (UAS7) as the primary efficacy endpoint).

    Time frame: Baseline, Week 12

  3. Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)

    The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity). This endpoint is a secondary endpoint for testing strategy Scenario 1 with Weekly Urticaria Activity Score (UAS7) as the primary efficacy endpoint.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Number of Patients Who Achieved Disease Activity Control (UAS7 ≤6)

    The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 12

  2. Number of Patients Who Achieved Complete Absence of Hives and Itch (UAS7 = 0)

    The number of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 12

  3. Number of Patients With Early Onset of Disease Control (UAS7 ≤ 6 at Week 2)

    The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 2

  4. Cumulative Number of Weeks With Disease Activity Control (UAS7 <= 6) up to Week 12

    Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: up to Week 12

  5. Number of Patients Who Achieved DLQI = 0 - 1

    The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients overall. DLQI = 0-1 means no effect on patient's life.

    Time frame: Week 12

  6. Cumulative Number of Weeks Without Angioedema (AAS7 = 0)

    Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).

    Time frame: Up to Week 12

  7. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

    Time frame: On-treatment adverse events are reported from first dose of study medication up to 28 days after last dose of study medication, for a timeframe up to approximately 56 weeks

07

Results

Posted Dec 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneLOU064 25mg b.i.d.Placebo
Started313157
Safety set309153
Full analysis set (fas)309153
Completed251124
Not completed6233
Withdrew: Technical problems01
Withdrew: Withdrawal by subject3117
Withdrew: Adverse event135
Withdrew: Unsatisfactory therapeutic effect43
Withdrew: Physician decision52
Withdrew: Lost to follow-up51
Withdrew: Protocol violation44

Outcome measures

PrimaryChange From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)

The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0. This endpoint is a secondary endpoint for testing strategy Scenario 2 with Weekly Itch Severity Score (ISS7) and Weekly Hives Severity Score (HSS7) as co-primary efficacy endpoints).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)
Scores on a scaleLOU064 25mg b.i.d.Placebo
Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)-20.02 ± 0.716-13.79 ± 0.980
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -6.22 · 95% CI -8.45 to -4.00MMRM adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, visit week, baseline score and both interaction of treatment by visit week and interaction of baseline score by visit week.
PrimaryChange From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)

The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity). This endpoint is a secondary endpoint for testing strategy Scenario 1 with Weekly Urticaria Activity Score (UAS7) as the primary efficacy endpoint).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)
Scores on a scaleLOU064 25mg b.i.d.Placebo
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)-9.52 ± 0.343-6.89 ± 0.470
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -2.63 · 95% CI -3.70 to -1.56MMRM adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, visit week, baseline score and both interaction of treatment by visit week and interaction of baseline score by visit week.
PrimaryChange From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)

The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity). This endpoint is a secondary endpoint for testing strategy Scenario 1 with Weekly Urticaria Activity Score (UAS7) as the primary efficacy endpoint.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)
Scores on a scaleLOU064 25mg b.i.d.Placebo
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints)-10.47 ± 0.401-6.86 ± 0.548
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.61 · 95% CI -4.85 to -2.36MMRM adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, visit week, baseline score and both interaction of treatment by visit week and interaction of baseline score by visit week.
SecondaryNumber of Patients Who Achieved Disease Activity Control (UAS7 ≤6)

The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Who Achieved Disease Activity Control (UAS7 ≤6)
ParticipantsLOU064 25mg b.i.d.Placebo
Number of Patients Who Achieved Disease Activity Control (UAS7 ≤6)15438
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.11 · 95% CI 2.00 to 4.84Logistic regression adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, and baseline UAS7 score.
SecondaryNumber of Patients Who Achieved Complete Absence of Hives and Itch (UAS7 = 0)

The number of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Who Achieved Complete Absence of Hives and Itch (UAS7 = 0)
ParticipantsLOU064 25mg b.i.d.Placebo
Number of Patients Who Achieved Complete Absence of Hives and Itch (UAS7 = 0)9616
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.83 · 95% CI 2.16 to 6.82Logistic regression adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, and baseline UAS7 score.
SecondaryNumber of Patients With Early Onset of Disease Control (UAS7 ≤ 6 at Week 2)

The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 2
Reported as:
Count of participants · Participants
Number of Patients With Early Onset of Disease Control (UAS7 ≤ 6 at Week 2)
ParticipantsLOU064 25mg b.i.d.Placebo
Number of Patients With Early Onset of Disease Control (UAS7 ≤ 6 at Week 2)1045
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 15.67 · 95% CI 6.18 to 39.77Statistical model used logistic regression adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics, and baseline UAS7 score.
SecondaryCumulative Number of Weeks With Disease Activity Control (UAS7 <= 6) up to Week 12

Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
up to Week 12
Reported as:
Least squares mean · weeks
Cumulative Number of Weeks With Disease Activity Control (UAS7 <= 6) up to Week 12
weeksLOU064 25mg b.i.d.Placebo
Cumulative Number of Weeks With Disease Activity Control (UAS7 <= 6) up to Week 125.17 ± 0.4141.92 ± 0.241
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Negative binomial regression model · p = <0.001 · Rate ratio: 2.69 · 95% CI 2.01 to 3.61Negative binomial regression model with log link, using treatment arm, geographical region, and prior exposure to anti-IgE biologics as covariates.
SecondaryNumber of Patients Who Achieved DLQI = 0 - 1

The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients overall. DLQI = 0-1 means no effect on patient's life.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Patients Who Achieved DLQI = 0 - 1
ParticipantsLOU064 25mg b.i.d.Placebo
Number of Patients Who Achieved DLQI = 0 - 112034
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.44 · 95% CI 1.53 to 3.90Statistical model used logistic regression adjusting for treatment arm, geographical region, prior exposure to anti-IgE biologics and baseline DLQI score.
SecondaryCumulative Number of Weeks Without Angioedema (AAS7 = 0)

Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).

Time frame:
Up to Week 12
Reported as:
Least squares mean · Weeks
Cumulative Number of Weeks Without Angioedema (AAS7 = 0)
WeeksLOU064 25mg b.i.d.Placebo
Cumulative Number of Weeks Without Angioedema (AAS7 = 0)8.43 ± 0.2746.72 ± 0.330
Statistical analysis
  • LOU064 25mg b.i.d. vs Placebo · Regression, Linear · p = <0.001 · Rate ratio: 1.25 · 95% CI 1.12 to 1.41Statistical model used a negative binomial regression with log link included treatment arm as fixed effect, geographical region, prior exposure to anti-IgE biologics, baseline AAS7 = 0 response as covariates.
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Time frame:
On-treatment adverse events are reported from first dose of study medication up to 28 days after last dose of study medication, for a timeframe up to approximately 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsDouble-blind Treatment Period: LOU064 25 mg b.i.d.Double-blind Treatment Period: PlaceboEntire Study Period: LOU064 25mg b.i.d.Open-label Period: Transitioned to LOU064 25 mg b.i.d.
Patients with at least one AE1888621862
Patients with serious or other significant events - Death0000
Patients with serious or other significant events - SAEs101131
Discontinued study treatment due to any AEs113152
Patients with serious or other significant events - Discontinued study treatment due to any SAEs2031
Patients with serious or other significant events - Treatment interruption due to AEs179183
Patients with serious or other significant events - Treatment interruption due to SAEs5150

Adverse events

Collected over On-treatment adverse events are reported from first dose of study medication up to 28 days after last dose of study medication, for a timeframe up to approximately 56 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LOU064 25mg b.i.d.0/309 (0%)13/309 (4.2%)139/309 (45%)
Placebo0/153 (0%)1/153 (0.7%)53/153 (34.6%)
Transitioned to LOU064 25mg b.i.d.0/133 (0%)1/133 (0.8%)26/133 (19.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventLOU064 25mg b.i.d.PlaceboTransitioned to LOU064 25mg b.i.d.
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/3090/1531/133
CholecystitisHepatobiliary disorders0/3091/1530/133
Angina pectorisCardiac disorders1/3090/1530/133
Cardiac failure congestiveCardiac disorders1/3090/1530/133
Gastrointestinal wall thickeningGastrointestinal disorders1/3090/1530/133
AppendicitisInfections and infestations1/3090/1530/133
COVID-19Infections and infestations1/3090/1530/133
Face injuryInjury, poisoning and procedural complications1/3090/1530/133
Diabetic ketoacidosisMetabolism and nutrition disorders1/3090/1530/133
HypokalaemiaMetabolism and nutrition disorders1/3090/1530/133
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLOU064 25mg b.i.d.PlaceboTransitioned to LOU064 25mg b.i.d.
COVID-19Infections and infestations31/30914/1536/133
HeadacheNervous system disorders25/30911/1533/133
NasopharyngitisInfections and infestations22/3095/1536/133
Urinary tract infectionInfections and infestations17/3094/1531/133
UrticariaSkin and subcutaneous tissue disorders11/3098/1532/133
DiarrhoeaGastrointestinal disorders11/3097/1532/133
Upper respiratory tract infectionInfections and infestations12/3092/1533/133
CoughRespiratory, thoracic and mediastinal disorders12/3092/1530/133
NauseaGastrointestinal disorders11/3093/1530/133
PetechiaeSkin and subcutaneous tissue disorders11/3091/1532/133

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LOU064 25mg b.i.d.PlaceboTotal
Mean44.6 ± 14.2745.9 ± 13.4445 ± 13.99
Age, Customized
Age, Customized(Participants)LOU064 25mg b.i.d.PlaceboTotal
>= 18 - < 65 years282143425
>= 65 - < 85 years311445
>= 85 years000
Sex: Female, Male
Sex: Female, Male(Participants)LOU064 25mg b.i.d.PlaceboTotal
Female212109321
Male10148149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LOU064 25mg b.i.d.PlaceboTotal
Hispanic or Latino7644120
Not Hispanic or Latino237113350
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LOU064 25mg b.i.d.PlaceboTotal
American Indian or Alaska Native121426
Asian9446140
Native Hawaiian or Other Pacific Islander011
Black or African American12315
White18889277
More than one race628
Unknown or Not Reported123
08

Study locations

112 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35209, United States
  • Novartis Investigative Site
    North Little Rock, Arkansas 72117, United States
  • Novartis Investigative Site
    Bakersfield, California 93301, United States
  • Novartis Investigative Site
    Lancaster, California 93534, United States
  • Novartis Investigative Site
    Los Angeles, California 90025, United States
  • Novartis Investigative Site
    Redwood City, California 94063, United States
  • Novartis Investigative Site
    Denver, Colorado 80230, United States
  • Novartis Investigative Site
    Aventura, Florida 33180, United States
  • Finlay Medical Research
    Greenacres City, Florida 33467, United States
  • Novartis Investigative Site
    Sarasota, Florida 34233, United States
  • Novartis Investigative Site
    Tallahassee, Florida 32308, United States
  • Novartis Investigative Site
    Albany, Georgia 31707, United States
  • Novartis Investigative Site
    Woodstock, Georgia 30188, United States
  • Novartis Investigative Site
    Evansville, Indiana 47715, United States
  • Novartis Investigative Site
    Chevy Chase, Maryland 20815, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68510, United States
  • Novartis Investigative Site
    Athens, Ohio 45701, United States
  • Novartis Investigative Site
    Columbus, Ohio 43235, United States
  • Novartis Investigative Site
    Toledo, Ohio 43617, United States
  • Novartis Investigative Site
    Tulsa, Oklahoma 74136, United States
  • Novartis Investigative Site
    Austin, Texas 78759, United States
  • Novartis Investigative Site
    El Paso, Texas 79924, United States
  • Novartis Investigative Site
    San Antonio, Texas 78213, United States
  • Novartis Investigative Site
    Sandy, Utah 84093, United States
  • Novartis Investigative Site
    Bellingham, Washington 98225, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1181ACH, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Buenos Aires, Nueve De Julio B6500BWQ, Argentina
  • Novartis Investigative Site
    Santa Fe, Rosario S2000DBS, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000JKR, Argentina
  • Novartis Investigative Site
    Bahia Blanca, B8000JRB, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000FIL, Argentina
  • Novartis Investigative Site
    Sydney, New South Wales 2010, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Medellin, Antioquia 050010, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlantico 080002, Colombia
  • Novartis Investigative Site
    Barranquilla, 080020, Colombia
  • Novartis Investigative Site
    Bogota, 110221, Colombia
  • Novartis Investigative Site
    Brno, Czech Republic 656 91, Czechia
  • Novartis Investigative Site
    Olomouc, CZE 779 00, Czechia
  • Novartis Investigative Site
    Plzen, 305 99, Czechia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Pierre Benite, 69495, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar 4026, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    New Delhi, Delhi 110 060, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 440012, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 440015, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422005, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500004, India
  • Novartis Investigative Site
    Varanasi, Uttar Pradesh 221005, India
  • Novartis Investigative Site
    Kolkata, West Bengal 700054, India
  • Novartis Investigative Site
    Belgavi, 590010, India
  • Novartis Investigative Site
    Chandigarh, 160012, India
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Torino, TO 10128, Italy
  • Novartis Investigative Site
    Obihiro, Hokkaido 080 0013, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 220-6208, Japan
  • Novartis Investigative Site
    Kamimashi-gun, Kumamoto 861-3106, Japan
  • Novartis Investigative Site
    Takatsuki, Osaka 569-8686, Japan
  • Novartis Investigative Site
    Koto, Tokyo 136-0074, Japan
  • Novartis Investigative Site
    Fukuoka, 819 0167, Japan
  • Novartis Investigative Site
    Hiroshima, 734-8551, Japan
  • Novartis Investigative Site
    Daegu, Dalseo Gu 42602, Korea, Republic of
  • Novartis Investigative Site
    Hwaseong si, Gyeonggi Do 18450, Korea, Republic of
  • Novartis Investigative Site
    Suwon si, Gyeonggi Do 16499, Korea, Republic of
  • Novartis Investigative Site
    Gwangju, 61469, Korea, Republic of
  • Novartis Investigative Site
    Incheon, 405 760, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 07061, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 07441, Korea, Republic of
  • Novartis Investigative Site
    Ciudad de Mexico, Distrito Federal 06700, Mexico
  • Novartis Investigative Site
    Guadalajara, Jalisco 44130, Mexico
  • Novartis Investigative Site
    Villahermosa, Tabasco 86035, Mexico
  • Novartis Investigative Site
    Carolina, 00985, Puerto Rico
  • Novartis Investigative Site
    San Juan, 00927, Puerto Rico
  • Novartis Investigative Site
    Izhevsk, 426061, Russian Federation
  • Novartis Investigative Site
    Singapore, 308205, Singapore
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46015, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35010, Spain
  • Novartis Investigative Site
    Madrid, 280796, Spain

Showing the first 100 of 112 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2023, 24 months.

Results were first posted in Dec 2024, 11 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 24 months is close to that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Sep 1, 2021
StartActual
Nov 30, 2021
Primary completionActual
Dec 27, 2023
CompletionActual
Jan 19, 2024
Results first posted
Dec 2, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05030311
Responsible party
Sponsor
First posted
Sep 1, 2021
Start date
Nov 30, 2021
Primary completion
Dec 27, 2023
Completion
Jan 19, 2024
Results posted
Dec 2, 2024
Last update
Apr 8, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion